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Objectives: A multi-centered observational study evaluated the efﬁ  cacy of zoledronic acid for 
improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal com-
pression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.
Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing 
oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evalu-
ated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence 
and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using 
a questionnaire.
Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evalu-
able for efﬁ  cacy. There was a measurable statistically signiﬁ  cant reduction in pain at rest and 
on movement as well as an improvement in the quality of life compared with baseline. Best 
results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of 
the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed 
satisfaction with the treatment
Discussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing 
the quality of life in patients with prostate cancer with bone metastasis. Its easy administration 
and good tolerability make zoledronic acid one of the principal therapeutic tools in the manage-
ment of patients with pain associated with bone metastasis from prostate cancer.
Keywords: bone metastasis, pain, prostate cancer, zoledronic acid
Introduction
Bone metastasis from blood-borne dissemination and the introduction of tumor cells into 
the bone alters the balance between osteoblasts and osteoclast. Although most cases of 
bone metastasis are osteolytic metastasis with an increase in reabsorption, some cancers 
predominate in the osteoblasts, such as in the prostate, but in which osteolysis is also 
present (Clarke et al 1991; Garnero et al 2000; Berruti et al 2001; Scher 2003).
Between 30% and 50% of patients with prostate cancer have multiple bone metas-
tasis because the diagnosis is made very late in the disease course (Berruti et al 2001). 
This pattern has not changed over the past 10 years. The incidence of bone metastasis 
is around 65% of patients with cancer of the prostate and also of those with breast 
cancer (Coleman 2001).
Although the clinical evolution of metastatic bone disease in prostate cancer is 
relatively protracted, the presence of metastasis is considered a sign of therapeutic 
failure, of hormone-resistance, and of tumor progression. The vital prognosis of the 
patients is obscured and morbidity – mortality is favored in the short to medium term 
(Berruti et al 2001; Coleman 2001; Scher 2003). Bone metastasis is one of the prin-
cipal causes of pain in patients with advanced-stage prostate cancer as well as one 
of the main clinical features of incapacity. Further, it is one of the most important Patient Preference and Adherence 2008:2 216
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complications of the disease and the principal cause of the 
loss in quality of life (QoL).
The principal symptom of  pain has very speciﬁ  c character-
istics, ie, pain on movement which declines at rest but which, 
in the advanced stage of the disease, becomes constant. Pain is 
short and intense, at times superﬁ  cially located, and is accom-
panied by contraction of the striated musculature proximal to 
the affected bone (Payne 1993). The increase in pain intensity 
in these patients when walking parallels the increase in the 
tumor progression. The onset of pain due to the metastasis 
is not easily foreseen and bears no direct relationship to the 
clinico-radiological status of the disease (Dreicer 1997).
Together with the pain due to bone metastasis, more 
severe pain is associated with skeletal complications, usually 
in subjects who are hormone resistant. Further, the patient’s 
QoL is drastically altered when other aspects such as patho-
logical fractures, hypercalcemia, spinal displacement and 
compression, and paraplegia are added (Scher 2003).
Therapeutic options are limited when patients are in 
an advanced stage of prostate cancer. The options include 
radiotherapy, systemic endocrine hormone therapy, and 
cytotoxic drugs, but the beneﬁ  t obtained is slight (Oh 2000). 
As recommended by the WHO (Rhiner and Kedziera 1999; 
Bruera), there is a need for adjuvant palliative therapy to 
control the principal symptom of pain when the pain persists 
despite the anti-tumor therapy.
Analgesic treatment of bone pain of metastatic origin is 
complex and often fails. Locally administered radiotherapy 
and/or of radioisotopes and analgesics are the options, 
together with the use of bisphosphonates. Bisphosphonates 
are an alternative strategy in the treatment of symptoms 
such as skeletal complications, even if they do not directly 
inﬂ  uence tumor progression and survival (Coleman 2000; 
Clamp et al 2004).
Bisphosphonates appear to be efﬁ  cacious in bone metasta-
sis, not only in alleviating pain and controlling tumor hyper-
calcemia, but also in pre-empting or minimizing adverse 
skeletal events (Averbuch 1993; Papapoulos et al 2000). 
They act as strong inhibitors of bone matrix reabsorption and, 
as such, are genuine suppressors of osteolysis. Osteoclastic 
expansion is reduced (inhibitor of tumor growth factor) and 
differentiation of macrophage – monocyte precursors is 
impeded (Coleman 1991; Warrel 1992; Rogers et al 1997; 
Major et al 2000).
Zoledronic acid is a third-generation bisphosphonate, 
with a side-chain that contains an imidazole ring. It has 4 
principal characteristics (Warrel 1992; Boisser et al 2000; 
Tassone et al 2000; Small et al 2003):
–  a strong inhibitor of osteoclastic bone reabsorption with a 
potency greater than that of ﬁ  rst- and second-generation 
bisphosphonates;
–  can be administered via the parenteral route, similar to 
its predecessor pamidronate, but is easier to manage and 
requires no more than 15 minutes for administration;
–  approved by the FDA for the treatment of bone 
metastasis and also for adverse events resulting from the 
metastasis;
–  use for bone metastasis resulting from prostate cancer is 
among its principal indications.
In an in vivo model of hypercalcemia induced in rats, 
zoledronic acid appears 850-fold more potent than palmi-
dronate and 4-fold more than etidronate or clodronate 
(Warrel 1992). FDA approval is based on the results of 3 
large-scale international clinical trials with  3,000 patients 
with cancer of the prostate, lung, and breast, and multiple 
myeloma. One of the best clinical trials (Saad et al 2002) 
studied 600 patients with bone metastasis resulting from 
advanced prostate cancer. Patients treated with zoledronic 
acid had a signiﬁ  cant reduction in the number of skeletal-
related events (SRE) (pathological fractures: vertebral or 
nonvertebral) and an alleviation in bone pain. All these were 
achieved with a minimum of toxicity compared with placebo. 
The patients received doses of 4 mg iv every 4 weeks. Saad 
et al (2004) evaluated the long-term role of zoledronic acid 
in the prevention of skeletal events in metastatic prostate 
cancer patients.
We report a multi-centered, prospective, observational 
open trial to evaluate the efﬁ  cacy of zoledronic acid in 
patients diagnosed as having prostate cancer with bone 
metastasis who were hormone-sensitive (HS; D-2 on the 
Whitmore-Jewett scale) or hormone-resistant (HR) in pro-
gression stage of the disease.
Material and methods
Design and study population
The observational, multi-centered, prospective, and descrip-
tive study was conducted in a group of patients with prostate 
cancer and bone metastasis receiving treatment with zole-
dronic acid. The principal objectives were to evaluate the 
improvement in pain management and functional status of 
the patient. Secondary objectives were tolerability and ease 
of administration of zoledronic acid.
Inclusion period
Between July 1, 2002 and July 30, 2004, 218 patients 
with prostate cancer and bone metastasis were recruited Patient Preference and Adherence 2008:2 217
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by 27 specialists in urology service, 15 specialists in pain 
units, and 2 specialists in oncology service from a total of 
33 hospitals throughout Spain.
Inclusion criteria
All patients needed to be male, over 18 years of age, 
diagnosed as having adenocarcinoma of the prostate with 
histology conﬁ  rmation, and who had undergone androgen 
deprivation. All patients were diagnosed with bone metastasis 
at recruitment based on bone scan and none of them received 
any prior treatment with bisphophonates.
The overall general status considered acceptable was 
Eastern Cooperative Oncology Group (ECOG)  2 and 
Karnofsky Index (KI)  70, and the presence of metastatic 
bone pain on movement measured on a visual analog scale 
(VAS) of  4 was essential for trial entry. Patients were not 
to have had, in the month before study commencement, any 
history of pathological fracture, episodes of spinal compres-
sion, or radiotherapy to the bone.
All patients could be classiﬁ  ed into 2 subgroups well 
characterized with the clinical and biochemical criteria 
available. Patients classiﬁ  ed as hormone-sensitive (HS) 
(n = 76, 36%) had a sensitivity response to hormonal treat-
ment determined by prostate-speciﬁ  c antigen (PSA) values 
behavior and by clinical response. Patients classiﬁ  ed as 
hormone-resistant (HR) (n = 135, 64%) showed therapeutic 
refractoriness to hormone manipulation determined by PSA 
values (increase  50% in 3 consecutive determinations), by 
the increasing analgesic demand, and the need to incorporate 
other anticancer treatments.
Exclusion criteria
Patients with hypersensitivity to zoledronic acid, to bisphos-
phonates, or to any excipients of the zoledronic acid formula-
tion; patients with noncompliance to medications and those 
considered potentially unreliable; patients with altered renal 
function with levels of creatinine  265 μmol/L (3 mg/dL) 
or clinically significant hypercalcemia ( 45 mmol/L; 
16 mg/dL); patients with deterioration in cognitive capacity 
and having difﬁ  culty in understanding the methodological 
requirements of the study. The antineoplasic therapy on 
trial entry and during the trial was at the discretion of the 
attending physician.
Ethics
All patients provided written informed consent and the study 
was conducted in accordance with the principles of Helsinki 
and the requirements of the Spanish government.
Data collection and description
of measures: efﬁ  cacy variables
Patients were extensively evaluated at baseline and at 6 and 
12 months of follow-up after treatment commencement with 
zoledronic acid.
A complete physical examination was performed and a 
detailed clinical history taken. A bone scan was performed 
routinely unless a previous scan had been performed within 
3 months and documented results were available. Blood and 
urine samples were taken for biochemical and hematological 
investigations. Pain at rest and on movement was assessed 
on the VAS. At the same visit all medications and analgesics 
already in use were recorded, the functional status on the 
ECOG scale and the KI was assessed, and the Lattinen and 
SF-36 questionnaires were completed
Pain measures
The principal variables were variation in pain and patient 
mobility using the VAS score to evaluate pain intensity at 
rest and on movement.
We used also the Lattinen scale composed of 5 categories: 
pain intensity, patient activity, pain frequency, use of 
analgesics, and hours of sleep. Each category comprises 
5 items scored from 0 (better) to 5 (worse). Maximum score 
of the Lattinen scale is 20; a decrease in score indicates an 
improvement in patient status. Pain alleviation scores on the 
scale of 0 to 4 were: 0 (no alleviation), 1 (slight alleviation), 
2 (moderate alleviation), 3 (considerable alleviation), 
4 (complete alleviation).
Quality of life measures
Parameters of functional status and quality of life (QoL) 
are included in the Eastern Cooperative Oncology Group 
(ECOG) scale, the Karnofsky Index (KI), and the SF-36 
questionnaire. Further, we used the questionnaire to assess 
patient satisfaction and reduction in analgesics use. The 
ECOG and KI status was evaluated every trimester. An 
increment in the ECOG and a decrease in the KI indicate 
a worsening of the patient’s functional status. The QoL 
SF-36 questionnaire was completed by the patient every 3 
months after inclusion into the study to evaluate their physi-
cal and mental status. The responses to each question were 
coded and recoded according to the “Manual of Scoring 
of the Spanish version of the Health Questionnaire SF-36” 
published by the Municipal Institute of Medical Investiga-
tion (MIMI) (Instituto Municipal de Investigación Médica 
[IMIM]). The overall results of the two scores derived from 
the questionnaire were translated to a scale from 0 (poorer Patient Preference and Adherence 2008:2 218
Gálvez et al
health) to 100 (better health). An increase in score indicated 
an improvement in the patient’s status.
The questionnaire on patient satisfaction (comprising 4 
items) was completed during the last consultation visit of the 
study, or at the time the patient decided to abandon the study 
for whatever motive. At the clinical visits in the study, all 
adverse effects reported by the patient reported during the 
consultation were recorded, whether or not related to the 
study medication.
Treatment employed
Zoledronic acid was administered at a dose of 4 mg/day iv 
infused over 15 minutes, every 4 weeks (± 1 week). Treated 
patients were followed up to the end of the study. Calcium 
and vitamin D supplements (daily tablet equivalent to 500 
mg/day calcium and 400 mg/day of vitamin D) were pro-
vided during the bisphosphonate treatment. Patients needed 
to start taking these supplements before the start of the 
bisphosphonates treatment, and needed to receive at least 1 
dose before the second consultation visit. The patients who 
abandoned the study before completing the treatment and for 
whom there had been at least 1 evaluation of status after the 
start of the study were considered evaluable on the intention-
to-treat analysis, taking as reference the last evaluation of 
response available prior to the patient abandoning the study. 
All patients who received at least 1 dose of the study drug 
were included in the safety analysis.
Duration of treatment 
and clinical consultations
Duration of evaluated treatment was 6 dose administrations 
in an interval of 3–5 weeks and a total of 18–30 weeks. 
However, patients continued treatment with zoledronic acid 
after the 6 sessions if the attending physician considered it 
necessary. The ﬁ  rst posttreatment assessment needed to be 
performed at 3 days after the ﬁ  rst dose. This was done by 
telephone to check for possible adverse effects. Subsequent 
visits were scheduled for the ﬁ  rst, second, third, fourth, ﬁ  fth, 
and sixth month. An investigator deciding that changing the 
treatment away from the study drug would be in the patient’s 
interest to was considered a valid treatment failure.
Data analyses and statistical tests
The variables are described using frequency tables and per-
centages for the qualitative variables, and included the mean, 
median, standard deviation, and range for the continuous 
variables. Comparisons of the variables of interest over the 
long term of the follow-up visits were carried out using the 
Wilcoxon nonparametric test (comparison of baseline data 
with the rest of the follow-up visits using paired sample 
test). Comparisons between subgroups of the study sample 
were carried out using the Whitney-Mann nonparametric test 
(2 groups) or the Kruskal-Wallis test (more than 2 groups). 
Qualitative variables were analyzed using contingency tables 
(χ2 test). All the statistical analyses were performed using 
the two-tailed test with α signiﬁ  cance of 5%. Efﬁ  cacy was 
evaluated using the at-rest and on-movement VAS. The 
Lattinen scale values were analyzed over the long term of the 
follow-up visits using the Wilcoxon nonparametric test and 
the comparison between subgroups using the nonparametric 
Mann-Whitney U test. All statistical analyses were performed 
using the SPSS package (version 12.0).
Results
Study sample description
A total of 218 male patients were included in the study 
(mean age 71.5 years; SD 7.5) (Table 1). Principal socio-
demographic and clinical characteristics of the population 
used in the evaluation of safety are those of the 212 patients 
who had received at least a single dose of zoledronic acid 
(Table 2). Of the cases, 170 (78.0%) were considered evalu-
able for analysis of effectiveness; 48 cases were excluded for 
not fulﬁ  lling inclusion/exclusion criteria (Table 2).
Data on timing of prostate cancer and bone metastasis 
diagnosis in both subgroups of patients (HS and HR) are 
shown on Table 3.
Pain
Patients had moderate decrease in pain over the ﬁ  rst month 
of treatment. As assessed on the VAS the at-rest scores 
decreased from 3.7 (SD 2.5) to 2.7 (SD 2.3) and reached 
2.3 points (SD 2.3) at the third evaluation. The at-rest pain 
was maintained close to this score over the subsequent 
months. Differences between baseline score and the remain-
ing months of follow-up were statistically signiﬁ  cant (Wil-
coxon test; p   0.0001) (Table 4). This effect was observed 
in HS and HR patients.
The on-movement VAS decreased from 6.0 (SD 2.0) to 4.6 
(SD 2.7) at the end of the ﬁ  rst month of treatment and to 4.2 
(SD 2.7) over the second month, and remained constant until the 
end of the study. Differences between baseline and the rest of 
the months of follow-up were statistically signiﬁ  cant (Wilcoxon 
test; p   0.0001) (Table 5). No differences were observed 
between HS and HR for on-movement VAS decrease.
In the ﬁ  rst month of treatment, 45.5% of the patients 
referred to the alleviation of pain as “none” or “slight” and Patient Preference and Adherence 2008:2 219
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27.9 indicated “considerable” or “complete” alleviation. At 
study end (6 months), percentage of patients with “none” or 
“slight” alleviation declined to 33.8% while patients with 
“considerable” or “complete” alleviation increased to 55.1%. 
Differences between baseline and follow-up were statistically 
signiﬁ  cant (Wilcoxon test; p   0.05).
The Lattinen index decreased from 9.0 points (SD 2.9) 
to 7.8 points (SD 3.6) at 2 months with a decrease during 
the ﬁ  rst month of treatment to 7.8 points (SD 3.6), and 
remained constant over the remaining months of follow-up 
and reached a score of 7.6 points (SD 4.3) at the sixth month. 
Statistically signiﬁ  cant differences were found for all months 
of follow-up (Mann-Whitney U test; p   0.05) as well as 
between baseline score and scores at the other months of 
follow-up visits in the overall study sample (Wilcoxon test; 
p   0.05). Patients were able to sleep an hour longer in the 
6 months of treatment, starting with a mean of 6.7 hours/day 
(SD 2.1) and at ending with a mean of 7.5 hours (SD 2.0). 
These differences were statistically signiﬁ  cant.
At the beginning of the study a total of 203 (95.8%) 
patients received analgesic treatment, which declined by 
10% after 4 months of treatment (Table 6).
At the start of the study, patients had a mean score on 
ECOG of 1.24 points (SD 0.57), at the third month 1.20 points 
(SD 0.75), and at the end of the follow-up period 1.31 points 
(SD 0.85). The differences for functional status did not reach 
statistical signiﬁ  cance between the baseline visit and that 
at the third and sixth months. Also we did not observe any 
differences in these values between HS and HR (Table 7).
During the 6 months of follow-up, mean score score on 
KI was approximately 80 points, which indicates that patients 
had, over the whole study, a functional status of   “good 
normal activity with some signs and symptoms of disease”. 
Scores at baseline and those at the third and sixth months of 
follow-up did not differ signiﬁ  cantly (Table 8).
The SF-36 questionnaire indicated a slight improvement 
in physical status. Signiﬁ  cant differences were observed 
between baseline scores and those at the third and sixth 
months of follow-up. No changes were observed for 
Table 1 Baseline clinical and demographic data
Characteristics N Percentage
Age, years
Mean ± SD 71.5 ± 7.5
Median 73
ECOG N = 207
 0 16 7.7
 1 114 55.1
 2 63 6.8
   2 14 6.8
KI N = 208
 100%–90% 48 23.1
 80% 84 40.4
 70% 52 25.0
   70% 24 11.5
Time since diagnosis 
of bone metastases
N = 172
 Mean  years  ± SD 0.9 ± 1.2
 Median 0.5
Location of bone 
metastases
N = 207
 Vertebral  column 125 60.4
 Ribs 96 46.6
 Pelvis 86 41.5
 Sacrum 57 27.5
 Femur 53 25.6
Abbreviation: KI, Karnofsky Index.
Table 2 Exclusion/inclusion criteria
n%
Total recruited cases 218 100.0%
Evaluable for efﬁ  cacy 170 78.0%
Not evaluable for efﬁ  cacy 48 22.0%
  Without bone metastasis evidence according to bone scan 4 1.8%
  Nonacceptable general health status to accomplish follow-up visits (ECOG  2 or I Karnofsky  70%) 28 12.8%
  Bone or metastatic pain absence (VAS on movement  2) 10 4.6%
  With pathological fracture or radiotherapy history one month prior to study 2 0.9%
  Altered renal function (creatinine  265 μmol/L or  3 mg/dL) 2 0.9%
  Patient without any zoledronic acid dose 8 3.7%
  Patient without basal pain and mobility improvement and without skeletal events onset time 9 4.1%
Abbreviation: VAS, visual analog scale.Patient Preference and Adherence 2008:2 220
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mental health between the baseline and the other follow-
up visits.
At the end of the study at 6 months, 66.3% of the 
patients said they were “very or sufﬁ  ciently satisﬁ  ed” 
with the treatment administered, 22.4% were “moderately 
satisﬁ  ed”, and 11.2% “not satisﬁ  ed”, with a mean of 55.4%, 
indicating that they had no objections to continuing with 
the treatment.
Adverse reaction
The most frequent adverse reactions were arthralgias, shiv-
ering, fever, edema, and constipation. Only 2 patients had 
severe adverse reaction, both after the ﬁ  rst dose: one had 
severe arthralgia and the other, who had a history of chronic 
renal insufﬁ  ciency, suffered hypocalcemia, hyperphostate-
mia, and acute renal failure. The rest of the patients showed 
good tolerance to the drug (Table 9). Pain was associated 
Table 3 Timing of prostate cancer diagnosis and bone metastasis
n Average SD Median p
Time elapsed since bone metastasis diagnosis (years) HS 68 0.6 0.8 0.3 0.0045
HR 103 1.1 1.4 0.7
Global 172 0.9 1.2 0.5 –
Time elapsed since prostate cancer diagnosis (years) HS 57 1.1 2.1 0.5 0.0000
HR 92 3.3 2.8 2.3
Global 150 2.5 2.8 1.4 –
Abbreviations: HR, hormone resistant; HS, hormone sensitive; SD, standard deviation.
Table 4 Score evolution (at rest VAS)
Global n SD Median pa
Basal 168 2.5 3.6 –
Month 1 169 2.3 2.0  0.0001
Month 2 169 2.4 2.0  0.0001
Month 3 169 2.3 2.0  0.0001
Month 4 169 2.4 2.0  0.0001
Month 5 169 2.6 2.0  0.0001
Month 6 169 2.6 2.0  0.0001
Hormone sensitive (HS)
Basal 58 2.5 3.0 –
Month 1 58 2.2 1.9  0.0001
Month 2 58 2.2 1.7 0.0001
Month 3 58 2.1 1.3  0.0001
Month 4 58 2.1 1.1  0.0001
Month 5 58 2.3 0.8 0.0015
Month 6 58 2.4 0.7 0.0001
Hormone resistant (HR)
Basal 110 2.4 4.0 –
Month 1 111 2.3 2.3 0.0008
Month 2 111 2.4 2.0  0.0001
Month 3 111 2.4 2.0  0.0001
Month 4 111 2.5 2.1 0.0053
Month 5 111 2.6 2.1 0.0034
Month 6 111 2.6 2.1 0.0038
aWilcoxon   Test: Comparison for basal resting VAS.
Abbreviations: SD, standard deviation;   VAS, visual analog scale.
Table 5 Score evolution (on-movement VAS)
Global n SD Median pa
Basal 169 2.0 6.0 –
Month 1 169 2.6 4.3  0.0001
Month 2 169 2.7 4.0  0.0001
Month 3 169 2.8 4.0  0.0001
Month 4 169 2.9 4.0  0.0001
Month 5 169 2.8 4.0  0.0001
Month 6 169 2.9 4.0  0.0001
Hormone sensitive (HS)
Basal 58 1.9 5.0 –
Month 1 58 2.5 4.0  0.0001
Month 2 58 2.5 3.0  0.0001
Month 3 58 2.6 3.2 0.0001
Month 4 58 2.6 2.5  0.0001
Month 5 58 2.7 2.5  0.0001
Month 6 58 2.8 2.8 0.0009
Hormone resistant (HR)
Basal 111 2.0 6.8 –
Month 1 111 2.6 5.0  0.0001
Month 2 111 2.7 4.0  0.0001
Month 3 111 2.8 4.3  0.0001
Month 4 111 2.9 5.0  0.0001
Month 5 111 2.8 4.3  0.0001
Month 6 111 2.9 4.9  0.0001
aWilcoxon   Test: Comparison for basal active VAS.
Abbreviations: SD, standard deviation;   VAS, visual analog scale.Patient Preference and Adherence 2008:2 221
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with bone metastasis and SRE. All of these were recorded 
in both HS and HR groups (Figure 1).
Discussion
Bone metastasis is the principal cause of morbidity in all 
types of cancer and the most-frequent cause of pain, espe-
cially that associated with movement. This pain results 
from release of prostaglandins causing a reduction in pain 
threshold, an increase in intra-bone pressure due to tumor 
invasion, and high periostial sensitivity. Pain from metastasis 
is often accompanied by limitation in the patient’s functional 
status resulting from fractures and skeletal lesions, which 
cause a drastic loss in QoL (Levy 1993; Paye 1993; Cózar 
Olmo et al 1999).
The ideal management of pain of metastatic bone origin 
would be elimination of the tumor. However, this is not an 
option in these patients and, hence, the objective is pain 
reduction. The priority is to alleviate on-movement pain 
such as that resulting from skeletal-related events. However, 
the complex treatment and frequent failure indicates that the 
approach needs to be multi-disciplinary, using the whole 
arsenal available for this type of pain. In this approach, 
Table 6 Pain treatment during follow-up
Basal Month 1 Month 2 Month 3
n% n % n % n %
Evaluable patients 212 100.0% 192 100.0% 160 100.0% 142 100.0%
Without analgesic treatment 9 4.2% 11 5.7% 12 7.5% 10 7.0%
With analgesic treatment 203 95.8% 181 94.3% 148 92.5% 132 93.0%
 NSAID/minor  analgesics 153 72.2% 132 68.8% 108 67.5% 92 64.8%
 Mild  Opioids 68 32.1% 58 30.2% 37 23.1% 31 21.8%
 Strong  Opioids 59 27.8% 61 31.8% 51 31.9% 44 31.0%
 Corticoids 20 9.4% 16 8.3% 13 8.1% 12 8.5%
Month 4 Month 5 Month 6
n% n% n%
Evaluable patients 127 100.0% 112 100.0% 104 100.0%
Without analgesic treatment 19 15.0% 10 8.9% 13 12.5%
With analgesic treatment 108 85.0% 102 91.1% 91 87.5%
 NSAID/Minor  analgesics 76 59.8% 72 64.3% 63 60.6%
 Mild  opioids 24 18.9% 22 19.6% 20 19.2%
 Strong  opioids 40 31.5% 34 30.4% 30 28.8%
 Corticoids 10 7.9% 10 8.9% 10 9.6%
Table 7 Functional status evolution according to ECOG scale
Na Average SD pb
Global Basal 169 1.24 0.57 –
Month 3 119 1.20 0.75 0.5687
Month 6 81 1.31 0.85 0.1196
Hormone sensitive (HS) Basal 58 1.09 0.54 –
Month 3 46 1.04 0.67 1.0000
Month 6 35 1.11 0.76 0.4669
Hormone resistant (HR) Basal 111 1.32 0.57 –
Month 3 73 1.30 0.79 0.5013
Month 6 46 1.46 0.89 0.1664
aIn some cases no data were available.
bComparison with ECOG basal visit score (Wilcoxon test).
Abbreviation: SD, standard deviation.Patient Preference and Adherence 2008:2 222
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bisphosphonates can play a signiﬁ  cant role (Gálvez 1998; 
Cózar Olmo et al 1999; Coleman 2000). First-generation 
bisphosphonates showed slight analgesic effectiveness in 
bone pain in patients with bone metastasis resulting from 
prostate cancer. Saad et al (2002) was the ﬁ  rst to demonstrate 
the usefulness of the zoledronic acid in these patients.
The results of the present study conﬁ  rm and comple-
ment those of Saad et al (2002). We analyzed additional 
variables such as pain at rest, pain on movement, ECOG 
scale of functional status, a mixed scale such as Lattinen 
that evaluates pain, sleep, and functional status, and a QoL 
questionnaire.
The at-rest VAS, as with the on-movement scores, 
improved relative to baseline. These differences were sta-
tistically different, albeit moderate in absolute terms within 
the ﬁ  rst month of treatment and over the whole 6-month 
follow-up period. Patients valued this factor highly, since 
the stability and some improvement in functional status were 
Table 8 Functional status evolution according to Karnofsky scale
na Average SD pb
Global Basal 169 79.9 7.6 –
Month 3 120 80.1 13.1 0.9536
Month 6 83 79.0 14.9 0.2837
Hormone sensitive (HS) Basal 58 81.6 7.2 –
Month 3 46 81.0 15.3 0.6883
Month 6 36 83.1 10.9 0.6424
Hormone resistant (HR) Basal 111 79.1 7.7 –
Month 3 74 79.6 11.6 0.8727
Month 6 47 76.0 16.9 0.0923
aIn some cases no data were available.
bComparison with Karnofsky basal visit score (Wilcoxon test).
Abbreviation: SD, standard deviation.
Table 9 Adverse reactions recorded
Type Total Hormone resistant (HR) Hormone sensitive (HS)
NR NP % NR NP % NR NP %
Muscle-skeletal 7 7 3.3 3 3 1.4 3 3 1.4
Arthralgia 3 3 1.4 1 1 0.5 2 2 0.9
Myalgia 2 2 0.9 1 1 0.5 0 0 0.0
Bone pain 2 2 0.9 1 1 0.5 1 1 0.5
Nervous system 4 4 1.9 1 1 0.5 3 3 1.4
Dizziness 3 3 1.4 1 1 0.5 2 2 0.9
Neuralgia 1 1 0.5 0 0 0.0 1 1 0.5
Gastrointestinal 14 11 5.2 8 6 2.8 4 4 1.9
Constipation 4 4 1.9 1 1 0.5 3 3 1.4
Diarrhea 1 1 0.5 1 1 0.5 0 0 0.0
Vomiting 5 5 2.4 4 4 1.9 0 0 0.0
Nausea 4 4 1.9 2 2 0.9 1 1 0.5
General body 20 15 7.1 9 6 2.8 11 9 4.2
Edema 3 3 1.4 2 2 0.9 1 1 0.5
Asthenia 2 2 0.9 2 2 0.9 0 0 0.0
Fever/shivering 5 5 2.4 3 3 1.4 2 2 0.9
Generalized illness 2 2 0.9 1 1 0.5 1 1 0.5
Generalized pain 3 3 1.4 1 1 0.5 2 2 0.9
Inﬂ  uenza-type symptoms 4 4 1.9 0 0 0.0 4 4 1.9
Abbreviations: NR, number of adverse reactions; NP, number of patients with adverse reactions (some patients had more than one adverse reaction).Patient Preference and Adherence 2008:2 223
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perceived as decisive QoL factors. This same perception can 
be applied to the attending physicians (oncology, urology, 
pain units) who consider that pain from bone metastasis is 
difﬁ  cult to treat because of the poor response to analgesics. 
The result is a progressive loss of QoL. As such, stabiliza-
tion over 6 months with zoledronic acid appears to be a big 
advance in terms of analgesia and QoL (Cherny and Portenoy 
1994; Cózar Olmo et al 1999). These data are conﬁ  rmed by 
comparing ECOG and KI status at baseline and end of study 
at 6 months.
Study patients were hormone-sensitive and hormone-
refractory, which is a major difference from the study of 
Saad et al (2002). Our results showed that zoledronic acid 
behaves similarly under both conditions.
As has been cited by various authors (Berruti et al 2001; 
Scher 2003; Papapoulos et al 2000; Saad et al 2002), the use 
of bisphosphonates in patients with bone metastasis from 
prostate cancer has two main objectives: to reduce pain and 
to help avoid bone fractures and adverse skeletal events. 
Skeletal lesions appear more frequently with the hormonal 
treatment employed in these patients because of the resultant 
loss in bone mass which, in addition to the metastasis, makes 
fractures more likely (Daniell 1997; Townsend et al 1997; 
Smith et al 2001).
Zoledronic acid needs to be an integral part of a 
multi-disciplinary treatment plan for bone metastasis 
resulting from prostate cancer, and should be the fruit of 
the collaboration between urologists, oncologists, radiolo-
gists, and pain management specialists (Berenson 2005). 
In addition to this drug, radiotherapy or use of radioactive 
isotopes (such as strontium) may be indicated as complement 
to an appropriate analgesic (Gálvez 1998; Cózar Olmo et al 
1999; Schmeler and Bastin 1996).
The low frequency of adverse effects (fever, arthralgia, 
constipation) and good tolerability observed with zole-
dronic acid in our study appeared not too different from 
that observed with other bisphosphonates, particularly that 
of pamidronate, and with less severe side-effects at the 
pharmacologically efﬁ  cacious dose of 4 mg iv a month. 
Similarly, although the parenteral route is less convenient, 
fewer digestive-tract disruptions occur than when taken 
orally (Adami and Zamberlan 1996; Saad et al 2002; 
Zojer et al 1999). Generalized arthralgias occur for around 
48 hours and are alleviated, or pre-empted, with paracetamol 
at a dose of 3 g/day. Renal function needs to be monitored. 
Our one patient who suffered renal dysfunction had been 
recruited despite having an elevated creatinine level. The 
renal dysfunction became apparent after the ﬁ  rst dose of the 
zoledronic acid.
The need for an iv dose administration of only once every 
4 weeks was perceived as comfortable and acceptable by 
most patients, and was a deciding factor in patients wishing 
to continue with this treatment.
In conclusion, we have demonstrated analgesic beneﬁ  t 
and good tolerability of zoledronic acid at the doses indicated 
in these patients with bone metastasis. The results conﬁ  rm 
and extend previous ﬁ  ndings. The reduced dose, ease of 
management, and periodicity of use promote zoledronic acid 
Figure 1 Skeleton-related events (SRE).
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as a ﬁ  rst-line drug in the management of patients suffering 
from advanced prostate cancer and bone metastasis.
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